Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

50 years of oral rehydration therapy: the solution is still simple.

Nalin DR, Cash RA.

Lancet. 2018 Aug 18;392(10147):536-538. doi: 10.1016/S0140-6736(18)31488-0. Epub 2018 Aug 16. No abstract available.

PMID:
30152375
2.

Single-Dose Vaccines.

Nalin DR.

J Infect Dis. 2015 Dec 15;212(12):2021. doi: 10.1093/infdis/jiv393. Epub 2015 Aug 12. No abstract available.

PMID:
26272933
3.

Ebola and cholera.

Nalin DR, Hirschhorn N.

Am J Trop Med Hyg. 2015 May;92(5):1081. doi: 10.4269/ajtmh.15-0169. No abstract available.

4.

Oral rehydration for cholera.

Nalin DR.

Clin Infect Dis. 2009 Mar 15;48(6):839-40; author reply 840-1. doi: 10.1086/597111. No abstract available.

PMID:
19220152
5.

Comment on: unexpected antimicrobial effect of statins.

Nalin DR.

J Antimicrob Chemother. 2008 Jun;61(6):1400. doi: 10.1093/jac/dkn089. Epub 2008 Mar 4. No abstract available.

PMID:
18321843
6.

Cholera or choleric?

Nalin DR.

Clin Infect Dis. 2008 Jan 1;46(1):150. doi: 10.1086/524088. No abstract available.

PMID:
18171236
7.

Oral therapy for cholera: amino acids added to electrolyte solutions containing rice or glucose.

Nalin DR, Cash RA.

J Infect Dis. 2006 Jan 15;193(2):331; author reply 331-2. No abstract available.

PMID:
16362900
8.

Zinc and cholera.

Nalin DR.

J Infect Dis. 2005 Nov 1;192(9):1672; author reply 1672-3. No abstract available.

PMID:
16206086
9.

The cover art of the 15 June 2004 issue.

Nalin DR.

Clin Infect Dis. 2004 Dec 1;39(11):1741-2. No abstract available.

PMID:
15578390
10.

Clinical concerns about reduced-osmolarity oral rehydration solution.

Nalin DR, Hirschhorn N, Greenough W 3rd, Fuchs GJ, Cash RA.

JAMA. 2004 Jun 2;291(21):2632-5. No abstract available.

PMID:
15173156
11.

Formulation of oral rehydration solution.

Hirschhorn N, Nalin DR, Cash RA, Greenough WB 3rd.

Lancet. 2002 Jul 27;360(9329):340-1. No abstract available.

PMID:
12147399
12.

CHOICE Study Group Trial.

Hirschhorn N, Nalin DR, Cash RA.

Pediatrics. 2002 Apr;109(4):713-5; author reply 713-5. No abstract available.

PMID:
11927719
13.
14.

Evidence based vaccinology.

Nalin DR.

Vaccine. 2002 Feb 22;20(11-12):1624-30. Review.

PMID:
11858871
15.

Recognition and treatment of anthrax.

Nalin DR.

JAMA. 1999 Nov 3;282(17):1624-5. No abstract available.

PMID:
10553786
16.

Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults.

Walter EB, Hornick RB, Poland GA, Tucker R, Bland CL, Clements DA, Rhamstine CC, Jacobson RM, Brown L, Gress JO, Harris KE, Wiens BL, Nalin DR.

Vaccine. 1999 Mar 17;17(11-12):1468-73.

PMID:
10195783
17.

Comparing immunogenicity of two measles, mumps and rubella vaccines.

Nalin DR.

Vaccine. 1999 Feb 5;17(5):508. No abstract available.

PMID:
10073730
18.

Serum antibodies to HIV-1 are produced post-measles virus infection: evidence for cross-reactivity with HLA.

Baskar PV, Collins GD, Dorsey-Cooper BA, Pyle RS, Nagel JE, Dwyer D, Dunston G, Johnson CE, Kendig N, Israel E, Nalin DR, Adler WH.

Clin Exp Immunol. 1998 Feb;111(2):251-6.

19.
20.

Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults.

Chen XQ, Bülbül M, de Gast GC, van Loon AM, Nalin DR, van Hattum J.

J Hepatol. 1997 Feb;26(2):260-4.

PMID:
9059944
21.

Hepatitis A vaccine.

Nalin DR.

J Occup Environ Med. 1996 Dec;38(12):1200-1. No abstract available.

PMID:
8978510
22.

O come, let us wallow in glorious mud.

Nalin DR.

Trans R Soc Trop Med Hyg. 1996 Nov-Dec;90(6):717. No abstract available.

PMID:
9015528
23.

Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.

Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR.

Pediatr Infect Dis J. 1996 Aug;15(8):687-92.

PMID:
8858673
24.

Duration of protection from clinical hepatitis A disease after vaccination with VAQTA.

Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, Brown L, Kuter BJ, Nalin DR.

J Med Virol. 1996 Jul;49(3):235-41.

PMID:
8818971
25.

Hepatitis infections in the day-care setting.

Hurwitz ES, Deseda CC, Shapiro CN, Nalin DR, Freitg-Koontz MJ, Hayashi J.

Pediatrics. 1994 Dec;94(6 Pt 2):1023-4. No abstract available.

PMID:
7971045
26.

Low incidence of adverse experiences after measles or measles-rubella mass revaccination at a college campus.

Seager C, Moriarity J, Ngai A, Staehle BO, Nalin DR.

Vaccine. 1994 Aug;12(11):1018-20.

PMID:
7975841
27.

Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era.

Johnson CE, Nalin DR, Chui LW, Whitwell J, Marusyk RG, Kumar ML.

Pediatrics. 1994 Jun;93(6 Pt 1):939-44.

PMID:
8190581
28.

Cholera and severe toxigenic diarrhoeas.

Nalin DR.

Gut. 1994 Feb;35(2):145-9. No abstract available.

29.

Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview.

Nalin DR, Kuter BJ, Brown L, Patterson C, Calandra GB, Werzberger A, Shouval D, Ellerbeck E, Block SL, Bishop R, et al.

J Hepatol. 1993;18 Suppl 2:S51-5. Review.

PMID:
8182275
30.
31.

Evaluating mumps vaccines.

Nalin DR.

Lancet. 1992 Feb 1;339(8788):305. No abstract available.

PMID:
1346304
32.

A simple antigen-reduction assay for the measurement of neutralizing antibodies to hepatitis A virus.

Krah DL, Amin RD, Nalin DR, Provost PJ.

J Infect Dis. 1991 Mar;163(3):634-7.

PMID:
1847404
33.

Mumps vaccine complications: which strain?

Nalin DR.

Lancet. 1989 Dec 9;2(8676):1396. No abstract available.

PMID:
2574335
34.

Mumps, measles, and rubella vaccination and encephalitis.

Nalin DR.

BMJ. 1989 Nov 11;299(6709):1219. No abstract available.

35.

Measles vaccine.

Nalin DR.

Rev Infect Dis. 1989 Nov-Dec;11(6):1035. No abstract available.

PMID:
2602773
36.

Ivermectin for human strongyloidiasis and other intestinal helminths.

Naquira C, Jimenez G, Guerra JG, Bernal R, Nalin DR, Neu D, Aziz M.

Am J Trop Med Hyg. 1989 Mar;40(3):304-9.

PMID:
2929853
37.

Comparison of oral rehydration solutions.

Nalin DR.

J Pediatr Gastroenterol Nutr. 1989 Feb;8(2):272-6. No abstract available.

PMID:
2709258
38.

Blood group A substances are not present in currently available pneumococcal vaccine.

Nalin DR, Morges W.

Vaccine. 1988 Dec;6(6):469-70. No abstract available.

PMID:
3245290
39.

Blood group substances in pneumococcal vaccine.

Nalin DR, Morges W.

Lancet. 1988 Sep 17;2(8612):695. No abstract available.

PMID:
2901561
40.

Use of norfloxacin to treat chronic typhoid carriers.

Gotuzzo E, Guerra JG, Benavente L, Palomino JC, Carrillo C, Lopera J, Delgado F, Nalin DR, Sabbaj J.

J Infect Dis. 1988 Jun;157(6):1221-5.

PMID:
3286783
41.

Bacterial resistance to norfloxacin and other newer quinolones: pattern and prospects.

Nalin DR.

Eur J Cancer Clin Oncol. 1988;24 Suppl 1:S55-61. Review. No abstract available.

PMID:
3280327
42.

Oral therapy for diarrheal diseases.

Nalin DR.

J Diarrhoeal Dis Res. 1987 Dec;5(4):283-92. No abstract available.

PMID:
3507438
43.

Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents.

Shungu DL, Nalin DR, Gilman RH, Gadebusch HH, Cerami AT, Gill C, Weissberger B.

Antimicrob Agents Chemother. 1987 Jun;31(6):949-50.

44.

Comparison of efficacy of oral rehydration fluids administered at 37 degrees C or 23 degrees C.

Pizarro DT, Posada GS, Levine MM, Nalin DR, Mohs EV.

J Trop Pediatr. 1987 Feb;33(1):48-51. doi: 10.1093/tropej/33.1.48. No abstract available.

PMID:
3573136
45.

Imipenem/cilastatin for pediatric infections in hospitalized patients.

Nalin DR, Hart CB, Shih WJ, Aziz MA.

Scand J Infect Dis Suppl. 1987;52:56-64.

PMID:
3331043
46.

Imipenem/cilastatin therapy for serious infections in neonates and infants.

Nalin DR, Jacobsen CA.

Scand J Infect Dis Suppl. 1987;52:46-55.

PMID:
3331042
47.

Effect on clinical outcome of breast feeding during acute diarrhoea.

Nalin DR.

Br Med J (Clin Res Ed). 1985 Apr 20;290(6476):1217. No abstract available.

48.

Death of child submitted to uvulectomy for diarrhoea.

Nalin DR.

Lancet. 1985 Mar 16;1(8429):643. No abstract available.

PMID:
2857982
49.

A point survey of periurban and urban malaria in Karachi.

Nalin DR, Mahood F, Rathor H, Muttalib A, Sakai R, Chowdhry MA, Safdar G, ul Haq I, Munir M, Suleiman M, et al.

J Trop Med Hyg. 1985 Feb;88(1):7-15.

PMID:
4020933
50.

Oral replacement of water and electrolyte losses due to travellers' diarrhoea.

Nalin DR.

Scand J Gastroenterol Suppl. 1983;84:95-8.

PMID:
6314492

Supplemental Content

Loading ...
Support Center